<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Bone marrow transplantation from HLA identical family donors is the treatment of choice for children with severe aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (SAA) </plain></SENT>
<SENT sid="1" pm="."><plain>When no donor is available, combined immunosuppressive therapy is given </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: Evaluation of results of immunosuppressive therapy in children with severe aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIAL AND METHODS: SAA was diagnosed in 85 children (31 girls, 54 boys) aged 2-17.5 years in the eleven centres of the Polish Paediatric <z:mpath ids='MPATH_336'>Leukaemia</z:mpath> and <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> Study Group (PPLLSG) in Poland between 1993-2003 years </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received protocol of the Severe Aplastic <z:hpo ids='HP_0001903'>Anaemia</z:hpo> Working Party of the Europe Bone Marrow Transplant (EBMT): antilymphocyte globulin or antithymocyte globulin, <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, <z:chebi fb="2" ids="8378">prednisolone</z:chebi> and granulocyto- or granulocyto-macrophagic-cell stimulation factor was additionally administered during deep <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Haematological response was evaluated on day 84, 112 or 180 of the therapy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: complete remission occurred in 43 patients (50.5%), partial remission in 22 (25.4%), no response was obtained in 20 children (23.7%) in 180 day of the therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Period of observation was from 12 months to 10.5 years </plain></SENT>
<SENT sid="8" pm="."><plain>During this time relapse occurred in 6 patients (7%) </plain></SENT>
<SENT sid="9" pm="."><plain>We observed 16 <z:hpo ids='HP_0011420'>deaths</z:hpo>: 7 early during the first 3 months of immunosuppressive therapy (IS) and 9 after the first 3 months of IS </plain></SENT>
<SENT sid="10" pm="."><plain>Conclusion: the actual survival at 10-years, after immunosuppressive therapy is 81.2% in our group </plain></SENT>
<SENT sid="11" pm="."><plain>Transformation to <z:mpath ids='MPATH_336'>leukaemia</z:mpath> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) was not observed in any of our patients </plain></SENT>
<SENT sid="12" pm="."><plain>We observed one case with <z:e sem="disease" ids="C0024790" disease_type="Disease or Syndrome" abbrv="PNH">paroxysmal nocturnal haemoglobinuria</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) </plain></SENT>
</text></document>